系统性红斑狼疮的新范式
本文综述了系统性红斑狼疮(SLE)异质性带来的挑战,讨论了欧洲抗风湿病联盟与美国风湿病学会的新分类标准、缓解与低疾病活动度的新定义、狼疮肾炎组织学分类的新提案,以及SLE治疗推荐和药物开发新方法,旨在安全降低疾病活动度、防止损伤累积和死亡。
要点
- SLE的异质性对遗传学家和临床研究者构成挑战。
- SLE患者预后已大幅改善,但仍需更安全有效的疗法。
- 需更好理解SLE发病机制与临床表型的关联。
核心结论
- SLE的异质性正挑战整个狼疮研究群体,需改进临床研究工具以克服表型异质性带来的障碍。
- SLE治疗推荐和药物开发新方法有望进一步改善SLE结局。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- SLE患者预后已大幅改善,但许多未满足需求仍存在,首要的是开发更安全有效的疗法。
- 需要更好理解SLE发病机制与一系列临床表型的关系。
- 需要完善现有临床研究工具并更好地适应以克服表型异质性造成的障碍。
关键数值与推荐
- 讨论了欧洲抗风湿病联盟与美国风湿病学会的新分类标准。
- 讨论了缓解和低狼疮疾病活动度的新定义。
- 讨论了狼疮肾炎组织学分类的新提案。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The heterogeneity of systemic lupus erythematosus (SLE), long recognised by clinicians, is now challenging the entire lupus community, from geneticists to clinical investigators. Although the outlook for patients with SLE has greatly improved, many unmet needs remain, chief of which is the development of safer and more efficacious therapies. To develop innovative therapies, a far better understanding of SLE pathogenesis as it relates to the array of clinical phenotypes is needed. Additionally, to efficiently achieve these goals, the lupus community needs to refine existing clinical research tools and better adapt them to overcome the obstacles created by the heterogeneity of manifestations. Here, we review progress towards the ultimate goal of safely reducing disease activity and preventing damage accrual and death. We discuss the new classification criteria from the European League Against Rheumatism and American College of Rheumatology, novel definitions of remission and low lupus disease activity, and new proposals for the histological classification of lupus nephritis. Recommendations for the treatment of SLE and novel approaches to drug development hold much promise to further enhance SLE outcomes.
引用
- Dörner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet. 2019. PMID: 31180031. doi:10.1016/S0140-6736(19)30546-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。